|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM378146599 |
| 003 |
DE-627 |
| 005 |
20240927233229.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240927s2024 xx |||||o 00| ||chi c |
| 024 |
7 |
|
|a 10.3760/cma.j.cn112140-20240210-00106
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1550.xml
|
| 035 |
|
|
|a (DE-627)NLM378146599
|
| 035 |
|
|
|a (NLM)39327960
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Song, L
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A multicenter study on effect of delayed chemotherapy on prognosis of Burkitt lymphoma in children
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.09.2024
|
| 500 |
|
|
|a Date Revised 27.09.2024
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Objective: To analyze the factors affecting delayed chemotherapy in children with Burkitt lymphoma (BL) and their influence on prognosis. Methods: Retrospective cohort study. Clinical data of 591 children aged ≤18 years with BL from May 2017 to December 2022 in China Net Childhood Lymphoma (CNCL) was collected. The patients were treated according to the protocol CNCL-BL-2017. According to the clinical characteristics, therapeutic regimen was divided into group A, group B and group C .Based on whether the total chemotherapy time was delayed, patients were divided into two groups: the delayed chemotherapy group and the non-delayed chemotherapy group. Based on the total delayed time of chemotherapy, patients in group C were divided into non-delayed chemotherapy group, 1-7 days delayed group and more than 7 days delayed group. Relationships between delayed chemotherapy and gender, age, tumor lysis syndrome before chemotherapy, bone marrow involvement, disease group (B/C group), serum lactate dehydrogenase (LDH) > 4 times than normal, grade Ⅲ-Ⅳ myelosuppression after chemotherapy, minimal residual disease in the interim assessment, and severe infection (including severe pneumonia, sepsis, meningitis, chickenpox, etc.) were analyzed. Logistic analysis was used to identify the relevant factors. Kaplan-Meier method was used to analyze the patients' survival information. Log-Rank was used for comparison between groups. Results: Among 591 patients, 504 were males and 87 were females, the follow-up time was 34.8 (18.6,50.1) months. The 3-year overall survival (OS) rate was (92.5±1.1)%,and the 3-year event-free survival (EFS) rate was (90.5±1.2)%. Seventy-three (12.4%) patients were in delayed chemotherapy group and 518 (87.6%) patients were in non-delayed chemotherapy group. The reasons for chemotherapy delay included 72 cases (98.6%) of severe infection, 65 cases (89.0%) of bone marrow suppression, 35 cases (47.9%) of organ dysfunction, 22 cases (30.1%) of tumor lysis syndrome,etc. There were 7 cases of chemotherapy delay in group B, which were seen in COPADM (vincristine+cyclophosphamide+prednisone+daunorubicin+methotrexate+intrathecal injection,4 cases) and CYM (methotrexate+cytarabine+intrathecal injection,3 cases) stages. There were 66 cases of chemotherapy delay in group C, which were common in COPADM (28 cases) and CYVE 1 (low dose cytarabine+high dose cytarabine+etoposide+methotrexate, 12 cases) stages. Multinomial Logistic regression analysis showed that the age over 10 years old (OR=0.54,95%CI 0.30-0.93), tumor lysis syndrome before chemotherapy (OR=0.48,95%CI 0.27-0.84) and grade Ⅲ-Ⅳ myelosuppression after chemotherapy (OR=0.55,95%CI 0.33-0.91)were independent risk factors for chemotherapy delay.The 3-year OS rate and the 3-year EFS rate of children with Burkitt lymphoma in the delayed chemotherapy group were lower than those in the non-delayed chemotherapy group ((79.4±4.9)% vs. (94.2±1.1)%, (80.2±4.8)% vs. (92.0±1.2)%,both P<0.05). The 3-year OS rate of the group C with chemotherapy delay >7 days (42 cases) was lower than that of the group with chemotherapy delay of 1-7 days (22 cases) and the non-delay group (399 cases) ((76.7±6.9)% vs. (81.8±8.2)% vs. (92.7±1.3)%, P=0.002).The 3-year OS rate of the chemotherapy delay group (9 cases) in the COP (vincristine+cyclophosphamide+prednisone) phase was lower than that of the non-chemotherapy delay group (454 cases) ((66.7±15.7)% vs. (91.3±1.4)%, P=0.005). Similarly, the 3-year OS rate of the chemotherapy delay group (11 cases) in the COPADM1 phase was lower than that of the non-chemotherapy delay group (452 cases) ((63.6±14.5)% vs. (91.5±1.3)%, P=0.001). Conclusions: The delayed chemotherapy was related to the age over 10 years old, tumor lysis syndrome before chemotherapy and grade Ⅲ-Ⅳ myelosuppression after chemotherapy in pediatric BL. There is a significant relationship between delayed chemotherapy and prognosis of BL in children
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a English Abstract
|
| 700 |
1 |
|
|a Jin, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Y H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, X M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Duan, Y L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, M C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhai, X W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, A S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, X J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dai, Y P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, L P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, L R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, B X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wei, H X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, K L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jin, R M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, X G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, H X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, H M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhuang, S S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, C J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Z F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mu, X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, K H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, F
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 62(2024), 10 vom: 02. Sept., Seite 941-948
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:62
|g year:2024
|g number:10
|g day:02
|g month:09
|g pages:941-948
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.cn112140-20240210-00106
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 62
|j 2024
|e 10
|b 02
|c 09
|h 941-948
|